ArticleBMC infectious diseases2025
A longitudinal study of antibody responses to endemic HCoV and novel SARS-CoV-2 among mother-child pairs in Zambia.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSeroprevalence estimates of endemic human coronaviruses (HCoV) and novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are limited in Zambia. Information on development of acquired immunity to endemic HCoV in early life is also scarce and the potential cross-protective effect of HCoV immunity on SARS-CoV-2 remains debatable. We investigated seroprevalence of endemic HCoV in mother-child dyads and SARS-CoV-2 in children and explored the association between HCoV and SARS-CoV-2 antibodies in children to elucidate coronavirus seroepidemiology in Zambia.
methodsWe measured endemic HCoV NL63, 229E, OC43 and HKU1 and SARS-CoV-2 Spike protein subunit 1 (S1) specific immunoglobulin G (IgG) using an immunoassay. We tested plasma samples collected from Zambian mother-child dyads before the coronavirus disease 2019 pandemic in 2018 and 2019, and during the pandemic in 2020 and 2021. We determined HCoV S1 IgG seropositivity in mothers and children and SARS-CoV-2 S1 IgG seropositivity in children. We correlated HCoV antibodies in the mother-child pairs and longitudinally profiled HCoV antibodies in children to investigate development of HCoV immunity and contribution of maternal immunity. We compared child HCoV S1 IgG and SARS-CoV-2 S1 IgG antibodies before and during the pandemic to explore cross-reactivity.
resultsHCoV and SARS-CoV-2 S1 IgG antibodies were detected among mothers and children. Child HCoV seroconversion occurred following waning of maternal immunity but there was no significant correlation between HCoV and SARS-CoV-2 S1 IgG before and during the pandemic. A rise in SARS-CoV-2 S1 IgG seroprevalence among children was observed following the second and third epidemic waves of the COVID-19 pandemic in Zambia.
conclusionsEndemic HCoV NL63, 229E, OC43 and HKU1 widely circulated and are acquired early in Zambia. SARS-CoV-2 seroprevalence in children speaks to the susceptibility of this population to infection that necessitates their inclusion in control measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.